| Objective: The aim of this study is to investigate the efficacy and safety of Xingnaoyizhi prescription for the treatment of post-stroke cognitive impairment of spleen deficiency,phlegm and stasis blockage,to clarify its pathogenesis on post-stroke cognitive impairment,and to provide new ideas for the prevention and treatment of post-stroke cognitive impairment.To provide new ideas for the diagnosis and treatment of post-stroke cognitive impairment in Chinese medicine,and to provide scientific basis for the rational use of clinical drugs.Methods: Sixty post-stroke cognitive impairment patients from Jinan Hospital of Integrated Traditional and Western Medicine were selected as the study subjects and randomly divided into treatment group and control group,with 30 cases in each group.The control group was given oral huperzine A tablets(0.05mg×48 tablets,Henan Tailong Pharmaceutical Co.,LTD.,National medicine approval number: H10940156),0.1mg twice a day.The treatment group was given Xingnaoyizhi Prescription orally,on the basis of the control group,for 8 weeks.Before and after treatment,Simple Intelligent Mental State Scale of Cognitive function(MMSE),Barthel Index Assessment Scale,Montreal Cognitive Assessment(MoCA)and TCM syndrome score were performed.Meanwhile,liver and kidney function,blood routine,coagulation function,urine routine,stool routine,blood lipids,and electrocardiogram were examined before and after treatment,and adverse reactions during treatment were recorded and statistically analyzed using SPSS 25.0 software in order to evaluate the clinical efficacy of patients.Results: A total of 60 patients were enrolled in the study,and there was no interruption or interruption of treatment in either group during treatment.The control group had 30 cases and the intervention group 30 cases.1.The two groups of basic data were statistically analyzed before treatment,and there was no statistical difference between the two groups.(P>0.05),indicating comparability.2.The MMSE,MOCA,Barthel scores and TCM syndromes scores of the two groups were statistically analyzed before treatment(P>0.05),indicating comparability.3.After treatment,patients in both groups showed significant improvement in MMSE scale,MoCA scale,Barthel index scale and TCM syndrome score scale,the difference was statistically significant(P<0.05),the treatment group was more effective than the control group,and there was a statistically significant difference in scores between the two groups after treatment(P<0.05).4.Total clinical efficacy: Overall clinical outcome measured by the MoCA scale.The efficacy was 87% in the treatment group and 67% in the control group.The treatment group had a significantly higher efficacy than the control group and this difference was statistically significant(P<0.05).5.Curative effect of TCM syndrome: The effectiveness of TCM syndrome treatment was determined using the TCM Syndrome Rating Scale,with an effectiveness rate of 87% in the main group and 60% in the control group.Treatment efficacy in the main group was significantly higher than in the control group.The difference was statistically significant(P<0.05).6.Safety analysis: Patients in the two groups showed no obvious discomfort symptoms during drug administration,no significant abnormalities in laboratory tests were detected,and no significant side effects were observed during treatment.Conclusion:1.Xingnaoyizhi prescription combined with huperzine A tablet has more obvious advantages than huperzine A tablet alone in improving TCM syndrome scores.2.Xingnaoyizhi prescription combined with huperzine A tablets has more advantages than huperzine A tablets alone in improving the score of MMSE,MoCA and Barthel scales.3.Xingnaoyizhi prescription has a good clinical effect on patients with post-stroke cognitive impairment who suffer from spleen deficiency,phlegm and blood stasis blocking collaterality.4.Xingnaoyizhi prescription is safe and reliable,and it has certain scientific significance and clinical usefulness. |
PDF Full Text Request